Runway Health Partnership and Multi-Pronged Commercial Strategy Underpin Buy Rating on 60 Degrees Pharmaceuticals

Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on 60 Degrees Pharmaceuticals, Inc. and increased the price target to $24.00 from $6.00.

Matthew Keller has given his Buy rating due to a combination of factors that support a favorable outlook for 60 Degrees Pharmaceuticals. He highlights that the new partnership with Runway Health’s telehealth platform is designed to streamline patient access to ARAKODA for malaria prevention, particularly among international travelers, which could meaningfully reduce barriers between patients and prescribers. By integrating ARAKODA into a direct-to-consumer, physician-led online travel medicine service, Keller believes the company can broaden its reach, enhance visibility of the drug, and set the stage for faster revenue growth.

Keller also points to the company’s demonstrated ability to grow ARAKODA sales, noting that net revenues have risen significantly year over year, albeit from a modest base, indicating positive commercial traction. He underscores management’s multi-pronged strategy—boosting product awareness, strengthening physician engagement, working with payers and pharmacies to improve affordability, and exploring additional indications such as babesiosis—as key drivers of future upside. In his view, the company is positioned within a large and insufficiently served infectious disease market, and successful execution on these initiatives, combined with the Runway Health partnership, could materially enhance the stock’s value, supporting his Buy rating and split-adjusted price target.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SXTP in relation to earlier this year.